Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AIM ImmunoTech Inc. filings document an immuno-pharma issuer centered on Ampligen (rintatolimod) and its public-company financing, clinical and governance disclosures. Recent 8-K reports cover material agreements, Regulation FD clinical updates for the DURIPANC pancreatic cancer study, amendments to equity distribution arrangements, warrant notices, and operating and financial results.
Registration statements and related exhibits disclose rights-offering terms, Series G Convertible Preferred Stock, common stock purchase warrants, beneficial-ownership limits, warrant agency arrangements, and shelf or at-the-market equity issuance mechanics. The filings also address risk factors, shareholder-rights modifications, corporate-governance items and capital-structure changes relevant to AIM's research-and-development drug business.
AIM ImmunoTech Inc. registered for resale up to 31,287,933 shares of Common Stock by the identified Selling Stockholders, consisting of shares issuable upon exercise of Class H and Class I Warrants and placement agent warrants. The prospectus states the company will not receive proceeds from resale by the Selling Stockholders; cash proceeds of approximately $14.5 million would result only if all Warrants and Placement Agent Warrants are exercised for cash. The filing lists 24,328,623 shares outstanding as of May 29, 2026 and discloses post‑exercise outstanding shares would be 55,616,556 assuming full exercise.
AIM ImmunoTech Inc. has filed to register up to 13,077,089 shares of common stock for resale by existing selling stockholders, including shares issuable from PIPE shares, Pre-Funded Warrants, Class J Warrants and June offering placement agent warrants. The company is not selling any shares in this transaction and will not receive proceeds from stockholder resales.
If all related Pre-Funded, Class J and placement agent warrants are exercised for cash, AIM would receive approximately $5.5 million in gross proceeds for general corporate purposes and working capital. In that scenario, common shares outstanding would rise from 27,724,245 as of June 12, 2026 to 40,801,334, an increase of about 47.17%, and the prospectus highlights significant dilution and NYSE American listing and penny stock risks.
AIM ImmunoTech Inc. is holding a virtual Special Meeting on July 15, 2026 to seek stockholder approval for multiple proposals that would permit issuances exceeding 19.99% of the Company’s outstanding common stock in several financing and conversion transactions and to approve a reverse stock split of up to 1‑for‑25.
The meeting covers approvals tied to (i) newly issued Class H, Class I and Class J warrants and the shares issuable upon their exercise, (ii) potential conversion or satisfaction of promissory notes (including the February 16, 2024 and November 18, 2025 notes), (iii) a board‑option reverse split up to 1‑for‑25, and (iv) an adjournment authority. The Board recommends voting FOR each proposal. Shares outstanding were approximately 27,724,245 as of June 15, 2026.
AIM ImmunoTech Inc. regained full compliance with NYSE American continued listing standards after receiving confirmation from NYSE Regulation. The prior deficiencies under Sections 1003(a)(i), (ii), and (iii) related to stockholders’ equity have been resolved, and the “.BC” below-compliance flag will be removed from its ticker.
To strengthen its equity position, AIM completed several capital-raising transactions, including a warrant exercise inducement for approximately $3.5 million in gross proceeds and two equity/warrant offerings generating about $2.4 million and $2.6 million. The Company believes its stockholders’ equity now exceeds the $6.0 million minimum required by NYSE American and will remain under continued listing monitoring procedures.
AIM ImmunoTech Inc. entered into definitive agreements for a registered direct offering and concurrent private placement totaling approximately $2.65 million in gross proceeds. The company is selling 2,554,119 registered shares at $0.5189 per share and matching unregistered shares or pre-funded warrants, plus Class J warrants for up to 10,216,476 shares.
The transaction also includes pre-funded warrants at a $0.001 exercise price and Class J warrants exercisable at $0.5189 per share following stockholder approval. If all pre-funded and Class J warrants are exercised for cash, AIM could receive about $5.3 million in additional gross proceeds. Net proceeds are earmarked for clinical drug manufacturing, current and planned Phase 3 trial activities, and working capital.
AIM ImmunoTech Inc. updated its corporate bylaws to change how most shareholder proposals are approved. Effective June 9, 2026, proposals other than director elections will pass with a majority of the votes cast, meaning only votes "for" or "against" are counted and abstentions and broker non-votes are excluded. Previously, these matters required approval by a majority in voting power of the shares present and entitled to vote. The amendment is detailed in an attached bylaw amendment filed as an exhibit.
AIM ImmunoTech Inc. is offering 2,554,119 registered shares of Common Stock at $0.5189 per share. The prospectus supplement describes a concurrent private placement to accredited investors for 771,503 unregistered shares, pre-funded warrants to purchase 1,782,616 shares and Class J warrants to purchase up to 10,216,476 shares. Net proceeds from the registered offering are estimated at approximately $1.2 million after placement agent fees and estimated offering expenses; proceeds are intended to support a planned Phase 3 trial for Ampligen, manufacture clinical drug supply and for working capital. The Common Warrants become exercisable only upon the Stockholder Approval Date and will expire five years thereafter; the Pre-Funded Warrants are exercisable immediately at $0.001 per share. The offering is on a reasonable best efforts basis with no minimum and is subject to lock-ups, placement agent compensation (cash fees and warrants), and NYSE American continued-listing risks.
AIM ImmunoTech Inc. has filed an S-1 to register up to 31,287,933 shares of common stock for resale by existing holders of Class H and Class I warrants and related placement agent warrants. AIM will not receive proceeds from these stockholder sales, though full cash exercise of the warrants could bring in about $14.5 million for general corporate purposes and working capital.
The filing highlights substantial potential dilution, as common shares could rise from 24,328,623 to 55,616,556 if all registered warrants are exercised. AIM describes its focus on developing Ampligen for late-stage pancreatic cancer and other oncology and antiviral indications, while also warning about NYSE American listing risks, possible penny stock status, and significant stock price volatility.
AIM ImmunoTech Inc. filed an update describing new investor-focused materials on its lead drug candidate Ampligen for Ebola virus disease preparedness. The company released a Virtual Investor “What This Means” video segment and an Ebola-focused investor presentation reviewing previously published preclinical data and regulatory groundwork.
Management discusses the ongoing Bundibugyo Ebola outbreak, the lack of approved targeted therapies or vaccines for this strain, and Ampligen’s immune‑modulating mechanism as a PAMP‑restricted TLR3 agonist. The materials highlight Biosafety Level 4 preclinical findings showing 100% survival with early Ampligen administration in a lethal Ebola mouse model and note orphan drug designations from U.S. and European regulators, while emphasizing that significant additional testing and human trials are still required.